Explore GEN family of websites, social media experiences, blogs and more.

Unleashing ideas.
Strengthening startups.

Back to search results
    Date submitted
  • 15-Feb-2018

Mederi Sciences, LLC

Abstract

The primary focus of the business will be to further develop the bio-engineered Super FGF wound healing molecule through Phase 1 of the FDA process and successfully exit via a buyout from a pharmaceutical company.

Additional Questions

Investor questions have not yet been answered for this business